BioSpace13h
Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
FDA Declares Shortage of Novo Nordisk’s Wegovy, Ozempic Over
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
BioWorld3d
Astrazeneca, Vertex, Axsome secure US FDA approvals in January
The U.S. FDA approved 12 drugs in January, falling below the 2024 monthly average of 19. Only three new molecular entities received approval, trailing the yearly average of just over four per month.
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Vertex Pharmaceuticals Inc. VRTX rallied 1.82% to $480.33 Thursday, on what proved to be an all-around grim trading ...
Hosted on MSN4d
Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?
With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...
Effingham Daily News6d
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
BioSpace6d
AlgoTx Stumbles in Non-Opioid Pain Trial Following Vertex’s Journavx Approval
AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...
Vertex grew headcount 13% for the second straight year
At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.